Features of the novel coronavirus infection in cancer patients

A novel coronavirus (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) is largely associated with various coagulopathies, which can lead to either bleeding and thrombocytopenia or hypercoagulation and thrombosis. Thrombohemorrhagic complications also could accompany the development of cancer process. In addition, circulating inflammatory biomarkers such as fibrin, D-dimer, P-selectin and von Willebrand factor (vWF) typical to both coronavirus infection and malignancy process are of special interest. In this review, we discuss potential interplay between COVID-19 and cancer related to endothelial dysfunction, platelets, and systemic inflammatory response syndrome. Most importantly, patients should be treated in early stage of the disease process when elevated levels of fibrinogen, D-dimer, vWF, and P-selectin are observed. The level of these markers will rise rapidly upon disease progression, followed by a cytokine storm, would evidence about a poor prognosis.

1. The Johns Hopkins Coronavirus Resource Center (CRC). Available at: https://coronavirus.jhu.edu.

2. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 (07.05.2021). М.: Министерство здравоохранения Российской Федерации, 2021. 225 с.

3. Vaduganathan M., Vardeny O., Michel T. et al. Renin–angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020;382(17):1653–9. https://doi.org/10.1056/NEJMsr2005760.

4. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052.

5. Tian L., Yuan X., Xiao J. et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893–903. https://doi.org/10.1016/S1470-2045(20)30309-0.

6. Gao Y.D., Ding M., Dong X. et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76(2):428–55. https://doi.org/10.1111/all.14657.

7. Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43. https://doi.org/10.1001/jamainternmed.2020.0994.

8. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

9. Guzik T.J., Mohiddin S.A., Dimarco A. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–87. https://doi.org/10.1093/cvr/cvaa106.

10. Liu C., Zhao Y., Okwan-Duodu D. et al. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17(3):519–27. https://doi.org/10.20892/j.issn.2095-3941.2020.0289.

11. Curigliano G., Banerjee S., Cervantes A. et al.; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320–35. https://doi.org/10.1016/j.annonc.2020.07.010.

12. Liang W., Guan W., Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. https://doi.org/10.1016/S1470-2045(20)30096-6.

13. Rüthrich M.M., Giessen-Jung C., Borgmann S. et al.; LEOSS Study Group. COVID-19 in cancer patients: clinical characteristics and outcome – an analysis of the LEOSS registry. Ann Hematol. 2021;100(2):383–93. https://doi.org/10.1007/s00277-020-04328-4.

14. Zhang L., Zhu F., Xie L. et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894–901. https://doi.org/10.1016/j.annonc.2020.03.296.

15. Mehta V., Goel S., Kabarriti R. et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020l;10(7):935–41. https://doi.org/10.1158/2159-8290.CD-20-0516.

16. Kuderer N.M., Choueiri T.K., Shah D.P. et al.; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–18. https://doi.org/10.1016/S0140-6736(20)31187-9.

17. Anka A.U., Tahir M.I., Abubakar S.D. et al. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2021;93(4):e12998. https://doi.org/10.1111/sji.12998.

18. Lazzaroni M.G., Piantoni S., Masneri S. et al. Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2021;46:100745. https://doi.org/10.1016/j.blre.2020.100745.

19. Zhu Z., Cai T., Fan L. et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020;95:332–9. https://doi.org/10.1016/j.ijid.2020.04.041.

20. Varga Z., Flammer A.J., Steiger P. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5.

21. Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–62. https://doi.org/10.1038/s41577-020-0331-4.

22. Barnes B.J., Adrover J.M., Baxter-Stoltzfus A. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. https://doi.org/10.1084/jem.20200652.

23. Henderson L.A., Canna S.W., Schulert G.S. et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059–63. https://doi.org/10.1002/art.41285.

24. Goshua G., Pine A.B., Meizlish M.L. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–e582. https://doi.org/10.1016/S2352-3026(20)30216-7.

25. Kowalewski M., Fina D., Słomka A. et al. COVID-19 and ECMO: the interplay between coagulation and inflammation – a narrative review. Crit Care. 2020;24(1):205. https://doi.org/10.1186/s13054-020-02925-3.

26. Gustine J.N., Jones D. Immunopathology of hyperinflammation in COVID-19. Am J Pathol. 2021;191(1):4–17. https://doi.org/10.1016/j.ajpath.2020.08.009.

27. Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28–33. https://doi.org/10.1038/s41591-020-01202-8.

28. Choudhary S., Sharma K., Silakari O. The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options. Microb Pathog. 2021;150:104673. https://doi.org/10.1016/j.micpath.2020.104673.

29. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 20211;33(3):127–48. https://doi.org/10.1093/intimm/dxaa078.

30. Giavridis T., van der Stegen S.J.C., Eyquem J. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–8. https://doi.org/10.1038/s41591-018-0041-7.

31. Asakura H., Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113(1):45–57. https://doi.org/10.1007/s12185-020-03029-y.

32. Moreno G., Carbonell R., Bodí M., Rodríguez A. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva (Engl Ed). 2021;45(1):42–55. https://doi.org/10.1016/j.medin.2020.06.006.

33. Liu Y., Sun W., Guo Y. Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets. 2020;31(4):490–6. https://doi.org/10.1080/09537104.2020.1754383.

34. Levi M., Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med. 2021;16(2):309–12. https://doi.org/10.1007/s11739-020-02601-y.

35. Yin S., Huang M., Li D., Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARSCoV2. J Thromb Thrombolysis. 2021;51(4):1107–10. https://doi.org/10.1007/s11239-020-02105-8.

36. Trachil J., Tang N., Gando S. et al. ISTH interim guidance on recognition and management of coagulohathy in COVID-19. J Thromb Haemost. 2020;18(2):1023–6. https://doi.org/10.1111/jth.14810.

37. Арутюнов Г.П., Козиолова Н.А., Тарловская Е.И. и др. Согласованная позиция экспертов Евразийской ассоциации терапевтов по некоторым новым механизмам патогенеза COVID-19: фокус на гемостаз, вопросы гемотрансфузии и систему транспорта газов крови. Кардиология. 2020;60(5):9–19. https://doi.org/10.18087/cardio.2020.5.n1132.

38. Debuc B., Smadja D.M. Is COVID-19 a new hematologic disease? Stem Cell Rev Rep. 2021;17(1):4–8. https://doi.org/10.1007/s12015-020-09987-4.

39. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. https://doi.org/10.1111/jth.14768.

40. Terpos E., Ntanasis-Stathopoulos I., Elalamy I. et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–47. https://doi.org/10.1002/ajh.25829.

41. Zuo Y., Estes S.K., Ali R.A. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876. https://doi.org/10.1126/scitranslmed.abd3876.

42. El Hasbani G., Taher A.T., Jawad A., Uthman I. COVID-19, antiphospholipid antibodies, and catastrophic antiphospholipid syndrome: a possible association? Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120978667. https://doi.org/10.1177/1179544120978667.

43. Qian Y., Xie H., Tian R. et al. Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. COPD J Chronic Obstr Pulm Dis. 2014;11:171–6. https://doi.org/10.3109/15412555.2013.831062.

44. Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9. https://doi.org/10.1111/jth.14817.

45. Shi C., Wang C., Wang H. et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study. Clin Transl Sci. 2020;13(6):1087–95. https://doi.org/10.1111/cts.12880.

46. Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–8. https://doi.org/10.1016/j.cca.2020.03.022.

47. Liu X., Zhang X., Xiao Y. et al. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. medRxiv. April 28, 2020. https://doi.org/10.1101/2020.04.23.20076851. [Preprint].

48. Patell R., Khan A., Bogue T. et al. Heparin induced thrombocytopenia antibodies in COVID-19. Am J Hematol. 2020 Jul 13. https://doi.org/10.1002/ajh.25935. [Online ahead of print].

49. Riker R.R., May T.L., Fraser G.L. et al. Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome. Res Pract Thromb Haemost. 2020;4(5):936–41. https://doi.org/10.1002/rth2.12390.

50. Vayne C., May M.A., Bourguignon T. et al. Frequency and clinical impact of platelet factor 4-specific antibodies in patients undergoing extracorporeal membrane oxygenation. Thromb Haemost. 2019;119(7):1138–46. https://doi.org/10.1055/s-0039-1688827.

51. Bemtgen X., Zotzmann V., Benk C. et al. Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19. J Thromb Thrombolysis. 2021;51(2):301–7. https://doi.org/10.1007/s11239-020-02217-1.

52. Khandelwal S., Ravi J., Rauova L. et al. Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway. Blood. 2018;132(23):2431–40. https://doi.org/10.1182/blood-2018-03-834598.